The Effect of Measured Radiotherapy Dose on Intrathecal Drug Delivery System Function. Issue 7 (23rd February 2021)

• Record Type: Journal Article
• Authors: Odell, Daniel W.; Albrechtsen, Richard D.; Sindt, Jill E.; Gole, Ryan; Brown, Spencer; Parsons, Matthew W.; Paxton, Adam B.; Sarkar, Vikren; Lloyd, Shane; Brogan, Shane E.; Tao, Randa
• Is Part Of: Neuromodulaton. Volume 24:Issue 7(2021)
• Page Start: 1204
• Page End: 1208
• Publication Date: 2021-02-23
• Subjects: Cancer pain -- equipment failure -- intrathecal drug delivery -- intrathecal pain pump -- intrathecal pump malfunction -- radiotherapy; Central nervous system -- Physiology -- Periodicals; Central nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ner.13372
• Languages: English
• ISSNs: 1094-7159

Abstract

ABSTRACT: Objectives: Radiation therapy (RT) and intrathecal drug delivery systems (IDDS) are often used concurrently to optimize pain management in patients with cancer. Concern remains among clinicians regarding the potential for IDDS malfunction in the setting of RT. Here we assessed the frequency of IDDS malfunction in a large cohort of patients treated with RT. Materials and Methods: Cancer patients with IDDS and subsequent RT at our institution from 2011 to 2019 were eligible for this study. Patients were excluded in the rare event that their IDDS was managed by an outside clinic and follow‐up documentation was unavailable. Eighty‐eight patients aged 22–88 years old (43% female, 57% male) representing 106 separate courses of RT were retrospectively identified. Patients received varying levels of radiation for treatment of cancer and cumulative dose to the IDDS was calculated. IDDS interrogation was subsequently performed by a pain specialist. Malfunction was recorded as deviation from the expected drug volume and/or device errors reported upon interrogation as defined by the manufacturer. Results: Total measured RT dose to the IDDS ranged from 0 to 18.0 Gy (median = 0.2 Gy) with median dose of 0.04 Gy/fraction (range, 0–3.2 Gy/fraction). Ten pumps received a total dose >2 Gy and three received ≥5 Gy. Eighty‐two percentage of patients had follow‐up with a pain specialist for IDDS interrogation and all patients underwent follow‐up with a healthcare provider following RT. There were zero incidences of IDDS malfunction related to RT. No patient had clinical evidence of radiation related pump malfunction at subsequent encounters. Conclusions: We found no evidence that RT in patients with IDDS led to device failure or dysfunction. While radiation oncologists and pain specialists should coordinate patient care, it does not appear that RT dose impacts the function of the IDDS to warrant significant clinical concern.